ELSEVIER
SAUNDERS

Nurs Clin N Am 40 (2005) 831–854

NURSING CLINICS
OF NORTH AMERICA

CUMULATIVE INDEX 2005

A

Abacavir, 156, 157

Abarelix, 80, 90–91

Abscess formation, at injection drug site in drug abusers, 351–352

Acarbose, 110

Accreditation agencies, nursing, role in disaster competency development and integration in nursing education, 455–456

Acquired immunodeficiency syndrome (AIDS), antiviral agents for HIV and, update on, **149–165**
- altered nutrition and, 162–164
- fusion inhibitors, 161
- goals of therapy, 155
- non-nucleoside reverse transcriptase inhibitors, 158
- nucleoside reverse transcriptase inhibitors, 156–157
- nursing care, 163
- protease inhibitors, 158–160
- recommendations for, 162
- case study, 149–150
- CD4 cell counts, 153–154
- diagnostic tests, 152–153
- viral load, 154
- viral progression, 151–152

Activity levels, in overweight children, school-based program to increase, **661–669**

Actos. *See* Pioglitazone.

Acute stress disorder, in response to disasters, 538
- assessment of dissociative symptom cluster in, 540
- comparison with post-traumatic stress disorder, 539
- medications for treatment of, 547–548

ADEs. *See* Adverse drug events.

Administration, university, commitment from for school-based health centers sponsored by schools of nursing, 613–614

Adolescents, impact of violence on, and role of school-based health centers, **671–679**
- nurse practitioner's role in risk reduction and resiliency building in school-based health centers, **649–660**
  - comprehensive risk assessment, 650–655
  - confidentiality and the need to share information, 655
  - developmental stages and risk behaviors, 649–650
  - Healthy People 2010 critical health objectives, 650
  - programs for, 656–660
  - trust and authenticity, 656
- prevention of sexually transmitted infections in, model program in school-based health center, **681–688**
- school-based program to increase nutritional knowledge and activity in overweight, 664–666

Adults, older. *See* Older adults.

Advanced practice nurses, nurse practitioners, role in disaster planning and response, **511–521**

Adverse drug events, reduction of, in community hospital setting, **25–32**
- failure mode event analysis, 29
- medication reconciliation process, 28–29
- standardized order sets, 29
- with high-risk medications, 29–31

Advexin, 92

Advocacy, patient, as strategy for acquiring affordable medications for seniors, 60–61

Agency for Healthcare Research and Quality, research on national emergency preparedness and response curriculum, 475–476

Agenerase. *See* Amprenavir.

Airway management, in children, in mass casualty incident, 531

Note: Page numbers of article titles are in **boldface** type.

0029-6465/05/$ – see front matter
doi:10.1016/S0029-6465(05)00102-7

© 2005 Elsevier Inc. All rights reserved.
nursing.theclinics.com

Alemtuzumab, 79, 84–85
Alendronate, 126–127
American College of Emergency Physicians, task force on emergency preparedness and response training in US, 469–470
barriers to implementation of recommended content, 470
American National Standards Institute, regulations for healthcare organizations on emergency preparedness and response, 494
American Organization of Nurse Executives, survey on nurses' roles in disaster management teams, 473
American Society of Testing and Materials, regulations for healthcare organizations on emergency preparedness and response, 494
Amprenavir, 160
Anastrazole, 79, 89
Angiogenesis inhibitors, in biotherapy for cancer, 86
Angiotensin receptor blocker therapy, for diabetics, 113–114
Angiotensin-converting enzyme (ACE) inhibitors, for diabetics, 113–114
Ankle brachial index, in arterial and venous ulcers of lower extremity, 395–396
Antibiotic resistance, **63–75**
action plan for, 71–73
globalization and, 66–67
mechanisms of, 68–69
newer agents to combat, 69–71
scope of the problem, 65–66
types of, 67–68
drug-resistant *Streptococcus pneumoniae*, 68
methicillin-resistant *Staphylococcus aureus*, 67
vancomycin-intermediate and -resistant *Staphylococcus aureus*, 67–68
Antibiotics, topical, in wound management, 221
Antidepressant therapy, new developments in, **95–105**
categories of interventions, 97–98
bright light therapy, 98
electroconvulsive therapy, 97
pharmaceutical therapy, 98
psychotherapy, 97
current medications, 99–103
cyclic antidepressants, 99–100
herbal remedies, 102–103
monoamine oxidase inhibitors, 99
other types, 101–102
selective serotonin reuptake inhibitors, 100–101
patient considerations, 103
short history of, 96–97
Antidote administration, to children, in mass casualty incident, 531
Antidotes, to vesicants, in treatment of chemotherapy extravasation wounds, 308–309
Antimicrobial dressings, in topical wound management, 220–221
Antineoplastic therapy, innovations in, **77–94**
biotherapy, 78–79, 82–88
alemtuzumab, 79, 84–85
arsenic trioxide, 79, 86–87
bevacizumab, 79, 88
bortezomib, 79, 85–86
cetuximab, 79, 88
gefitinib, 79, 87
gemtuzumab ozogomicin, 79, 85–86
ibritumomab, 78, 83–84
imatinib mesylate, 79, 85
tositumomab, 78, 84
chemotherapy, 77–82
capecitabine, 78, 82
docetaxel, 78, 82
fludarabine phosphate, 78, 81
oxaliplatin, 77–78, 81
polifeprosan 20 with carmustine implant wafer, 78, 81–82
hormonal therapy, 79–80, 88–91
abarelix, 80, 90–91
exemestane, 79, 89
fulvestrant, 80, 90
letrozole, 80, 90
leuprolide, 80, 90
in the pipeline, 91–92
advexin, 92
epratuzumab, 91
oblimersen sodium, 91
virulizin, 91
Antiseptic agents, in topical wound management, 219–220
Antiviral agents, for HIV and AIDS, update on, **149–165**
altered nutrition and, **162–164**
fusion inhibitors, 161
goals of therapy, 155
non-nucleoside reverse transcriptase inhibitors, 158

nucleoside reverse transcriptase inhibitors, 156–157
nursing care, 163
protease inhibitors, 158–160
recommendations for, 162

Arimidex. *See* Anastrazole.

Aromasin. *See* Exemestane.

Arsenic trioxide, biotherapy for cancer with, 79, 86–87

Arterial ulcers, of lower extremity, **391–410**
anatomy, 392
characteristics, 397–398
pathophysiology, 397
risk factors, 401
treatment, 402–403

Aspirin therapy, in diabetics, 111

Asthma medications, evaluation of children's metered-dose inhaler technique for, **167–182**
new devices, 173–179
results of study of, 168–173

Atazanavir, 160

Atorvastatin, 112

Autolytic debridement, of wounds, 242

Avandia. *See* Rosiglitazone.

Avastin. *See* Bevacizumab.

Azidothymidine (AZT), 156, 157

Azidovudine. *See* Azidothymidine (AZT).

B

Bacteria, in chronic wounds, 196–197

Bacterial loads, control of, in topical wound management, 218–221

Barcode-enabled point-of-entry systems, prevention of medication errors with, 10–12

Bedding. *See* Support surfaces.

Behavioral therapy, in psychological care for disaster victims, 542, 545

Beidler levels of ethical issues framework, in nurse-managed health care centers, 766–767

Beta blocker therapy, for heart failure, **135–148**
clinical trials, 138–141
guidelines for administration, 145–146
nursing implications, 141–145

Bevacizumab, 79, 88

Bexxar. *See* Tositumomab.

Biopsy, of wounds, 298

Bioterrorism. *See also* Mass casualty incidents., Centers for Disease Control cooperative agreement on public health preparedness and response for, 489
federal funding for programs on health care planning and preparedness for, 488
Health Resources and Services Administration national hospital preparedness program for, 489
issues in preparing for, 500–501
role of public health nurses in planning for and responding to, 501–508

Biotherapy, cancer treatment with, innovations in, 78–79, 82–88
alemtuzumab, 79, 84–85
arsenic trioxide, 79, 86–87
bevacizumab, 79, 88
bortezomib, 79, 85–86
cetuximab, 79, 88
gefitinib, 79, 87
gemtuzumab ozogomicin, 79, 85–86
ibritumomab, 78, 83–84
imatinib mesylate, 79, 85
tositumomab, 78, 84
wound debridement using, 244

Bisprolol, 144

Blenaxis. *See* Abarelix.

Blood pressure, in arterial and venous ulcers of lower extremity, 395–396

Bone mineral density, in osteoporosis, 119–133
types of tests for, 125

Bortezomib, 79, 85–86

Bright light therapy, for depression, 98

Bupropion, 101

C

Cadexomer, wound debridement with, 242

Calcitonin, 127

Calcium, for osteoporosis prevention, 123–125
good sources of, 126
recommended intakes, 126

Campath. *See* Alemtuzumab.

Cancer, antineoplastic therapy, innovations in, **77–94**

Cancer patients, wound care in, **295–323**
atypical wounds associated with cancer, 297
cancer development in chronic wounds, 297–304
biopsy of, 298
causes of, 298

Cancer patients (*continued*)
malignant cutaneous wounds, 298–304
chemotherapy extravasation wounds, 303–310
impaired wound healing in, 296
radiation therapy, skin wounds due to, 310–317

Candidiasis, in obese patients, skin and wound considerations, 327–328

Capecitabine, 78, 82

Careers, in health care, exposing students in school-based health centers to, 641–644

Carvediol, 138–146

CD4 cell counts, in HIV infection, 153–154

Center for Integrated Health Care, integrated primary and mental health care at, **779–790**

Centers for Disease Control, cooperative agreement on public health preparedness and response for, 489
Strategic National Stockpile of, 486

Centers for Medicare and Medicaid Services, report on reducing health care disparities using nurse-managed health centers, 735–738

Cetuximab, 79, 88

Chemical debridement, of wounds, 241

Chemotherapy, innovations in, 77–82
capecitabine, 78, 82
docetaxel, 78, 82
fludarabine phosphate, 78, 81
oxaliplatin, 77–78, 81
polifeprosan 20 with carmustine implant wafer, 78, 81–82

Chemotherapy extravasation, 303–310
complications of, 306
impaired healing of wounds due to, 306
mechanisms of tissue damage in, 305
prevention of, 307
signs and symptoms of, 306
treatment of, 307–310
new directions in, 310

Childhood obesity. *See* Obesity, childhood.

Children. *See also* Adolescents *and* Pediatric care.
homeless, health care program for, **791–801**

Chronic venous insufficiency, in injection drug users, 352

Chronic wounds. *See* Wounds, chronic.

Classification systems, for pressure ulcers, 368

Cleansing, wound, in topical wound management, 219

Cocaine, injection drug users, wound care issues in, **349–363**

Cognitive status, in older adults, impact on wound care, 273–274

Cognitive strategies, in psychological care for disaster victims, 545

Collaboration, of public health nursing and primary care nursing in development of nurse-managed health center, **771–778**
with key partners, in school-based health centers, **689–697**

Colonization, in chronic leg and pressure ulcers, 209

Community, research on, in disaster preparedness and response, 557–558

Community health nursing, using Omaha System to document wellness needs of the elderly, **817–829**

Community hospital, reduction of adverse drug events and medication errors in, **25–32**

Community nursing centers, reduction of health care disparities via collaboration with practice-based research networks, **747–758**

Community partnerships, funding for school-based health centers from, 621

Community-based nurse managed practice, sustainment of, **739–745**

Community-based participatory research, reduction of health care disparities via, **747–758**

Competence, cultural, models of, for school-based health centers, 637–638

Competencies, nursing, in disasters, development and integration in nursing education, **453–467**

Compliance, with care, in prevention of pressure ulcers in people with spinal cord injury, 343–344

Compression, for venous ulcers, 403–404

Computerized provider order entry, prevention of medication errors with, 10–12

Conceptual analysis, of emergency preparedness and response in nursing practice, **419–430**
antecedents, 424
consequences, 424
defining attributes, 423–424
definition, 422–423

empirical referents, 424–425
literature review, 420–422
model case, 425–426
proposed definition of, 426
related concepts, 425
relevance for nursing, 426–427

Confidentiality, and need to share information on adolescents' risk behaviors in school-based health center, 655

Contamination, in chronic leg and pressure ulcers, 209

Continuing education providers, role in disaster competency development and integration in nursing education, 456

Cooking with Heart and Soul, resiliency programs in school-based health centers, 656

Coverage, Medicare, of support surfaces, 258–262

Crisis incident stress debriefing, for disaster victims, 545–547

Crixivan. *See* Indinavir.

Cultural aspects, of working with students enrolled in school-based health center, **637–647**
challenges of, 638–639
cultural diversity, 638
exposing students to health careers in, 643–646
models of cultural competence, 639–640
practice recommendations, 640–643

Cultural competence, models of, for school-based health centers, 639–640

Culture, hospital, changes in, to reduce adverse drug events and medication errors, **25–32**
impact of disaster on self, identity, and, **431–440**
See also Organizational culture.

Curriculum, nursing, competency development and integration in disaster nursing education, **453–467**
disaster nursing, development of based on vulnerability assessment in Pacific Northwest, **441–451**
bioterrorism curriculum enhancement, 450
competencies and content, 450
deficits in, 447
defining and validating competencies, 445–446
endorsement of competencies by experts, 446–447
professional nursing mandate, 449
state and regional imperatives, 449
survey responses, 447–448
vulnerability assessment, 442–443
vulnerable populations, 443–445
national curriculum in emergency preparedness and response, **469–479**
American Association of Nurse Executives' survey on, 473
American College of Emergency Physicians task force on, 469–470
evaluation of outcomes, 476–478
initial public health workforce competency development, 471
International Nursing Coalition for Mass Casualty Education role in, 471–473
national curriculum development efforts, 475–476
National Health Professions Preparedness Consortium, 473–475
online development of, 475

Cutaneous wounds, malignant. *See* Malignant cutaneous wounds.

Cyclic antidepressants, 99–100

D

Dalbavancin, 69

Daptomycin, 69–70

Death, and dying. *See* End-of-life care.

Debridement, of wounds, **233–249**
benefits of, 233–235
evidence-based practice and, 237–238
healing process, barriers and facilitators of, 235
in topical management, 218
methods of, 238–246
factors influencing choice of, 239
special role of, 236–237

Debriefing, psychological, for disaster victims, 545–547

Decontamination, of children, in mass casualty incident, 531

Deep tissue injury, pressure ulcers and, 369–370

Delaviridine, 159

Department of Health and Human Services, funding for school-based health centers through, 619

Depression, new developments in therapy for, **95–105**
categories of interventions, 97–98
bright light therapy, 98
electroconvulsive therapy, 97
pharmaceutical therapy, 98
psychotherapy, 97
current medications, 99–103
cyclic antidepressants, 99–100
herbal remedies, 102–103
monoamine oxidase inhibitors, 99
other types, 101–102
selective serotonin reuptake inhibitors, 100–101
patient considerations, 103
short history of therapy for, 96–97

Dermal replacement, active wound therapy with, 229–230

Dermatitis, incontinence, in obese patients, skin and wound considerations, 327–328

Desyrel. *See* Trazodone.

Diabetes, multidimensional pharmacologic strategies for, **107–117**
angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker therapies, 113–114
aspirin therapy, 111
glucose controlling agents, 114–116
lifestyle effects and modifications, 108–110
oral medications, 110–111
statin therapy, 111–113

Didanosine, 156, 157

Disaster competency, development and integration into nursing education, **453–467**

Disaster planning. *See* Emergency preparedness and response.

Disaster preparedness. *See* Emergency preparedness and response.

Disasters, human factors in, **581–588**
approaches used to reduced worldwide, 584–586
international collaboration, 585
international humanitarian aid agencies, 584–585
international laws, 585–586
how people contribute to, 582–584
classification of victims, 582–583
exposure to environmental hazards, 584
failure to provide social, economic, and health infrastructure, 582
impact on culture, self, and identity, **431–440**
evaluation of the effect, 434–438
feelings associated with trauma, 436–437
remembrance and mourning, 437–438
resilience and vulnerability, 435–436
holistic and transcultural perspectives, 432–433
nature of, 432
theoretical perspectives, 433–434

Diskus inhalers, for asthma medications, 178

Disparities, in health care, Centers for Medicare and Medicaid Services report on, 733–737
reduction of, practice-based research networks, collaboration with nursing centers and communities in, **747–758**
with nurse-managed health centers as safety net, **729–738**

Docetaxel, 78, 82

Documentation, of wellness needs of the elderly, use of Omaha System for, **817–829**

Dressings, guidelines for topical wound management, **217–231**
active therapies, 227–230
electrical stimulation, 229
growth factors, 228
matrix metalloproteinase inhibitors, 228
negative pressure wound therapy, 228–229
dressing selection, 224–227
deep dry wounds, 224–225
deep wet wounds, 224
human skin equivalents, 229–230
monochromatic infrared energy, 229
shallow dry wounds, 226–227
shallow wet wounds, 225–226
principles of, 217–223
control of bacterial loads, 218–221
debridement, 218, 240
establishment of open wound edges, 221

exudate management, 221–222
maintenance of moist wound surface, 222–223
maintenance of protected insulated wound surface, 223

Drug abuse, injection drug users, wound care issues in, **349–363**

Drugs, prescription, antibiotic resistance, **63–75**
current trends in use of, **33–49**
health promotion drug use, 36
primary prevention drug use, 37–38
secondary prevention drug use, 38–39
tertiary prevention drug use, 40–43

Dry powder inhalers, for asthma medications, 176–178

Dying, processes of, 285–287
activity changes, 286
at time of death and after, 287–288
elimination changes, 287
food and fluid intake changes, 286
imminent death, 287
mental changes, 285–286

E

Edges, wound, establishment of open, in topical wound management, 221

Education, on drug safety, role in prevention of medical errors, 13
on pressure ulcers in people with spinal cord injury, for health professionals, 345
for the patient, 342–343
on wound care, for injection drug users, 348
patient, as strategy for acquiring affordable medications for seniors, 60–61
See also Nursing education.

Efavirenz, 159

Effexor. *See* Venlafaxine., 101

Elderly. *See also* Senior citizens.
using Omaha System to document wellness needs of, **817–829**

Electrical stimulation, active wound therapy with, 229

Electroconvulsive therapy, for depression, 97

Elementary school administrators, perspectives on school-based health centers sponsored by schools of nursing, 615–616

Eligard. *See* Leuprolide.

Eloxatin. *See* Oxaliplatin.

Emergency preparedness and response, 419–588
concept development for nursing practice, **419–430**
antecedents, 424
consequences, 424
defining attributes, 423–424
definition, 422–423
empirical referents, 424–425
literature review, 420–422
model case, 425–426
proposed definition of, 426
related concepts, 425
relevance for nursing, 426–427
human factors in disasters, **581–588**
approaches used to reduced worldwide, 584–586
international collaboration, 585
international humanitarian aid agencies, 584–585
international laws, 585–586
how people contribute to, 582–584
classification of victims, 582–583
exposure to environmental hazards, 584
failure to provide social, economic, and health infrastructure, 582
impact of disaster on culture, self, and identity, **431–440**
evaluation of the effect, 434–438
feelings associated with trauma, 436–437
remembrance and mourning, 437–438
resilience and vulnerability, 435–436
holistic and transcultural perspectives, 432–433
nature of, 432
theoretical perspectives, 433–434
in nursing education, 453–479
curriculum development based on vulnerability in Pacific Northwest, **441–451**
disaster competency development and integration in, **453–467**
national curriculum for nurses on, **469–479**
in nursing practice, homeland security challenges, **481–497**

Emergency (*continued*)
nurse practitioners' role in, **511–521**
pediatric care in, **523–533**
psychological considerations in, **535–550**
public health nurses' role in, **499–509**
research issues in, **551–565**
state of the science in hospital response, **567–579**
web resources on, 542

Emotional recovery, in disasters, and psychiatric sequelae, 537–540

Emtricitabine, 158

Emtriva. *See* Emtricitabine.

End-of-life care, **281–294**
end-of-life processes, 285–287
activity changes, 286
at time of death and after, 287–288
elimination changes, 287
food and fluid intake changes, 286
imminent death, 287
mental changes, 285–286
end-of-life trajectories, 282–283
family involvement in, 284–285
palliative care concepts, 283–284
wound care at, nursing process for, 282, 288–293
assessment, 288–289
diagnosis and planning, 289–290
evaluation, 293
interventions, 290–293

Enfuvirtide, 161

Environmental factors, in prevention of medical errors, 17–18

Environmental Protection Agency, regulations for healthcare organizations on emergency preparedness and response, 494

Enzymatic debridement, of wounds, 243

Epidermal growth factor receptors, in biotherapy for cancer, 87–88

Epivir. *See* Lamivudine.

Epratuzumab, 91

Equipment factors, in prevention of medical errors, 17–18

Equipment, supportive, for obese patients, planning for, 334

Erbitux. *See* Cetuximab.

Errors, medication. *See* Medication errors.

Ethical issues, considerations for nurse-managed health care centers, **759–770**
Beidler levels of ethical issues framework, 766–767
dilemmas, conflicts, and issues in, 761–766
related to managed care, 767–768

Evaluations, of school-based health center programs and services, **711–724**

Exemestane, 79, 89

Extravasation, chemotherapy, 303–310
complications of, 306
impaired healing of wounds due to, 306
mechanisms of tissue damage in, 305
prevention of, 307
signs and symptoms of, 306
treatment of, 307–310
new directions in, 310

Exudate, management of, in topical wound management, 221–222

Eye movement desensitization and reprocessing, in psychological care for disaster victims, 545

Ezetimibe, 113

F

Faculty practice, at school-based health centers sponsored by schools of nursing, 611

Faculty, of schools of nursing, perspectives on school-based health centers sponsored by schools of nursing, 615–616

Failure mode and effects analysis, in prevention of medical errors and adverse drug events, 17, 29

Families, of patients, role in wound care at end of life, 284–285

Family, research on, in disaster preparedness and response, 557–558

Faslodex. *See* Fulvestrant.

Federal grants, for school-based health centers, 618–619

Femera. *See* Letrozole.

Flaps, tissue, failure of, due to infection, 212

Fludara. *See* Fludarabine phosphate.

Fludarabine phosphate, 78, 81

Fluid administration, in children, in mass casualty incident, 531

Foam mattresses. *See* Support surfaces.

Forteo, 127

Fortovase. *See* Saquinavir.

Foundations, funding for school-based health centers from, 622–623

Fulvestrant, 80, 90

Functional status, in older adults, impact on wound care, 274–275

Funding, for school-based health centers, **619–636**
federal grants, 620–621
foundations, 624–625
local funding and community partnerships, 623–624
patient care revenues, 625–626
state grants, 621–623

Fusion inhibitors, antiviral therapy with, in HIV infection, 161

Future Health Professionals club, resiliency programs in school-based health centers, 657–658

Fuzeon. *See* Enfuvirtide.

G

Gefitinib, 79, 87

Gemfibrozil, 112

Gemtuzumab ozogomicin, 79, 85–86

Genasense. *See* Oblimersen sodium.

Gender differences, in osteoporosis, 121–122

Generic medications, as strategy for acquiring affordable medications for seniors, 53–57

Geriatrics. *See also* Elderly *and* Older adults.
strategies for acquiring affordable medications for seniors, **51–61**

Gleevec. *See* Imatinib mesylate.

Gliadel. *See* Polifeprosan 20 with carmustine implant wafer.

Glipizide, 110

Globalization, antibiotic resistance and, 66–67

Glucophage. *See* Metformin.

Glucose control, in diabetics, oral medications for, 110–111, 114–116

Glucotrol. *See* Glipizide.

Glyset. *See* Miglitol.

Grafts, skin, failure of, due to infection, 212

Grants, for school-based health centers,
Federal, 620–621
state, 621–623

Growth factors, changes in chronic wounds, 197–199
topical, active wound therapy with, 228

H

Hazardous Waste Operations and Emergency Response, 494

Healing scales, for pressure ulcers, 375

Healing, wound, delay in, due to microorganisms, 209–211
impairment of, in cancer patients, 296
in extravasation wounds, 306
in older adults, 269–270

Health care disparities, reduction of, practice-based research networks, collaboration with nursing centers and communities in, **747–758**
with nurse-managed health centers as safety net, **729–738**

Health care organizations, compliance and regulatory issues for, in emergency preparedness and response programs, 489–493

Health centers, nurse-managed, 729–831
collaboration of public health and primary care nursing in development of, **771–778**
ethical considerations for, **759–770**
health care program for homeless children at, **791–801**
integrating primary and mental health care at, **779–790**
nurse home visiting with pregnant women, **803–815**
practice-based research networks at, **747–758**
safety net at, to reduce health disparities, **729–738**
sustaining nurse-managed practice, **739–745**
using Omaha system to document wellness needs of the elderly, **817–829**
school-based, 595–722
childhood obesity, school-based approach to, **661–669**
collaborating with key school partners, **687–697**
cultural aspects of working with students enrolled in, **637–647**
evaluation of program effectiveness, **711–724**
funding, technical assistance, and other resources for, **619–636**
history and overview of, **595–606**
impact of violence on adolescents, **671–679**
interdisciplinary teamwork in, **699–710**
nurse practitioner's role in adolescent risk reduction and resiliency building in, **649–660**
school of nursing sponsorship, challenges and barriers of, **607–617**

Health centers (*continued*)
STI-HIV prevention model for, **681–688**

Health history, and wound healing in injection drug users, 353–354
drug use history, 355–356
physical, 353–354
psychosocial, 354

Health insurance, patient care revenues as funding source for school-based health centers from, 623–624

Health promotion drugs, prescription, current trends in use of, 36

Health Resources and Services Administration, national bioterrorism hospital preparedness program, 489

Health systems, research on, in disaster preparedness and response, 558–560

Healthy People 2010, critical health objectives for adolescents, 650
health care program for homeless children using objectives from, **791–801**

Healthy Teens, resiliency programs in school-based health centers, 659

Hearing losses, in older adults, impact on wound care, 270–272

Heart failure, beta blocker therapy for, **135–148**
clinical trials, 138–141
guidelines for administration, 145–146
nursing implications, 141–145
pathophysiology of, 135–137

Hemostasis, in process of tissue repair, 192–193

Herbal remedies, over-the-counter, for depression, 102–103

Heroin, injection drug users, wound care issues in, **349–363**

High school administrators, perspectives on school-based health centers sponsored by schools of nursing, 615–616

History. *See* Health history.

Hivid. *See* Zalcitabine.

Holistic health care, perspectives on disaster in, 432–433

Home health care setting, professional fact sheet on Medicare coverage for support surfaces in, 259–262

Home visits, with pregnant women, in Nurse-Family Partnership, **803–815**

Homeland security, challenges in nursing practice related to, **481–497**
Centers for Disease Control's cooperative agreement on public health preparedness for, 489
compliance and regulatory issues for health care organizations, 489–493
Health Resources and Services Administration national bioterrorism hospital preparedness program, 489
incident command system/incident management system, 493–495
key knowledge base areas, 483–488
literature review of nursing's contributions, 482–483

Homeland Security Act of 2002, 488

Homeland Security Presidential Directives, 488

Homeless shelters, health care program for children at, **791–801**
background, 792–793
evaluation of, 798–799
implementation of, 793–798
implications for nursing practice, 799–800

Honey, wound debridement using, 245

Hormonal therapy, for cancer, innovations in, 79–80, 88–91
abarelix, 80, 90–91
anastrazole, 79, 89
exemestane, 79, 89
fulvestrant, 80, 90
letrozole, 80, 90
leuprolide, 80, 90

Hospice care, coverage and reimbursement for support surfaces in, 263

Hospital response, to acute-onset disasters, current state of, **567–579**
Milstein's state of science, findings in, 569–572
foundation of, as defined by, 568–569
gaps in, 572–575
value of examining, 567–568
value of review in patient care, 575–576

Human factors, in disasters, **581–588**
approaches used to reduced worldwide, 584–586
international collaboration, 585

international humanitarian aid agencies, 584–585
international laws, 585–586
how people contribute to, 582–584
classification of victims, 582–583
exposure to environmental hazards, 584
failure to provide social, economic, and health infrastructure, 582

Human immunodeficiency virus (HIV), antiviral agents for, update on, **149–165**
altered nutrition and, 162–164
fusion inhibitors, 161
goals of therapy, 155
non-nucleoside reverse transcriptase inhibitors, 158
nucleoside reverse transcriptase inhibitors, 156–157
nursing care, 163
protease inhibitors, 158–160
recommendations for, 162
case study, 149–150
CD4 cell counts, 153–154
diagnostic tests, 152–153
prevention of, model program in school-based health center, **681–688**
viral load, 154
viral progression, 151–152

Human skin equivalents, active wound therapy with, 229–230

Humanitarian aid agencies, international, 584–585

Hydrating dressings, in topical wound management, 221–222

Hydrofluoroalkane, in new metered-dose inhalers for asthma medications, 174

Hydrogen peroxide, wound debridement with, 242

Hydrotherapy, wound debridement with, 241

Hypobaric therapy, wound debridement with, 244

Hypochlorites, wound debridement with, 241

I

Ibritumomab, 78, 83–84

Identity, impact of disaster on culture, self, and, **431–440**

Imatinib mesylate, 79, 85

Incident Command System, for emergency management, 493–495

Incident Management System, for emergency management, 493–495

Incontinence dermatitis, in obese patients, skin and wound considerations, 327–328

Indinavir, 159

Infection, microbiology of, in chronic leg and pressure ulcers, **207–216**

Infections, at injection drug site in drug abusers, 351–352

Inflammatory responses, in process of tissue repair, 192–193

Information, medical, accessibility to, role in prevention of medical errors, 12–13

Inhalers, metered-dose, for asthma medications, evaluation of children's technique with, **167–182**

Injection drug users, classes of drugs and consequences, 349–350
injection process, 350–351
on heroin and cocaine, 350
wound care issues in, **349–363**
abscess and infection in, 351–352
chronic venous insufficiency in, 352–353
drug use history, 355–356
nutrition and, 354–355
pain and, 356–357
patient teaching for, 358–360
physical health history and, 353–354
prevention of wounds in, 360–361
psychosocial health history and, 354
wound assessment in, 357–358

Injury, tissue. *See* Wounds and Wound care.

Insulin therapy, 116

Insurance, health, patient care revenues as funding source for school-based health centers from, 623–624

Integrated care, primary and mental health care, in nurse-managed center for clients with serious and persistent mental illness, **779–790**

Interdisciplinary learning, for nursing students, at school-based health centers sponsored by schools of nursing, 611–612

Interdisciplinary team, in skin and wound care of obese patients, 332–333

Interdisciplinary teamwork, in a school-based health center, **709–710**

International humanitarian aid agencies, 584–585

International laws, humanitarian, 585–586

International Nursing Coalition for Mass Casualty Education, 454–455, 471–473
survey of nursing programs' content, 472–473

Invirase. *See* Saquinavir.

Iressa. *See* Gefitinib.

Ischemic ulcers, 406

J

Joint Commission on Accreditation of Healthcare Organizations, oversight of emergency preparedness and response programs, 490–493
comprehensive emergency management, 491–493
expectations of organizations, 490

JumpSTART algorithm, for pediatric triage in mass casualty incidents, 527–528

K

Kaletra. *See* Lopinovir *and* Ritonavir.

L

Lamivudine, 156, 157

Laser debridement, of wounds, 245

Lavage, pulsed, wound debridement with, 241

Learning, interdisciplinary, for nursing students, at school-based health centers sponsored by schools of nursing, 611–612

Leg ulcers. *See also* Lower extremity.
chronic, microbiology of, **207–216**
clinical approach to patients with, 212–213
clinical consequences of microorganisms within, 209–212
delay in wound healing, 209–211
infection, 211–212
skin graft and tissue flap infections, 212
contamination, colonization, and infection, 209

Legal considerations, in skin and wound care of obese patients, 330–332

Legislation, international humanitarian laws, 585–586
on homeland security and related regulations for health care organizations, 483–495

Legislative action, regarding affordable medications for seniors, 52–53

Letrozole, 80, 90

Leuprolide, 80, 90

Liability, medical, of nurse practitioners in disaster care, 516–517

Lifestyle modifications, for diabetics, 108–110

Linezolid, 70–71

Living 101, resiliency programs in school-based health centers, 657

Long-term care, coverage and reimbursement for support surfaces in, 263

Lopinavir, 160

Lovastatin, 112

Lower extremity *See also* Leg ulcers.
arterial and venous ulcers, **391–410**
anatomy, 392–393
arterial ulcers, 396–398
history and physical examination, 393–398
blood pressure and ankle brachial index, 395
inspection, 394–395
palpation, 395
vascular testing, 396
ischemic ulcers, 406
nursing management, 406
risk factors, 401
treatment, 402–407
venous ulcers, 398–401

M

Maggot debridement, of wounds, 244

Malignant cutaneous wounds, 298–304
assessment of, 299
characteristics of, 299
local wound management, 300–303, 304
treatment options for, 299–300

Malpractice coverage, liability of nurse practitioners in disaster care, 516–517

Managed care, ethical issues related to in nurse-managed health care centers, 767–768

Management skills, for school-based health centers sponsored by schools of nursing, 614

Marjolin's ulcer, 297

Mass casualty education, development and integration of into nursing education, **453–467**
International Nursing Coalition for Mass Casualty Education, 454–455, 471–473

See also Emergency preparedness and response.

Mass casualty incidents, pediatric care in, practical considerations for, **523–533**
challenges in, defining pediatric patients, 524–525
error-prone drug calculations, 525
developing standards for, 524
modify emergency interventions as needed, 530–532
pediatric triage systems, 527–530
pre-event planning, 523–524, 525–527
research issues in preparedness for, **551–565**
See also Emergency preparedness and response.

Maternal-child nursing, nurse home visits with pregnant women, in Nurse-Family Partnership, **803–815**

Matrix metalloproteinase inhibitors, active wound therapy with, 228

Mattresses. *See* Support surfaces.

Medicaid, patient care revenues as funding source for school-based health centers from, 623–624

Medical liability, of nurse practitioners in disaster care, 516–517

Medicare coverage and reimbursement, of support surfaces, 258–262

Medication errors, creating an organizational culture to avoid, **1–23**
inevitability of human error, 4–7
interventions to prevent, 8–18
adherence to established policies and procedures, 10
administrative support for, 17
education regarding drug safety, 13–14
environment and equipment, 17–18
failure mode and effects analysis, 17
information accessibility, 12–13
nonpunitive approach, 14–15
patient involvement, 9
staffing, 15–17
teamwork, 15
technology, 10–12
reduction of, in community hospital setting, **25–32**
scope of the problem, 1–4

Medication safety, creating an organizational culture for, **1–23**

Medications, psychotherapy for acute and post-traumatic stress disorder, 547–548

Mental health care, integrated primary care and, in nurse-managed center for clients with serious and persistent mental illness, **779–790**

Mental illness, serious and persistent, integrated primary and mental health care in nurse-managed center for clients with, **779–790**

Metered-dose inhalers, for asthma medications, evaluation of children's technique with, **167–182**

Metformin, 111, 114, 116

Methicillin-resistant *Staphylococcus aureus*, 67

Metoprolol, 138–146

Metropolitan Medical Response System, 486–487

Microbiology, of chronic leg and pressure ulcers, **207–216**
clinical approach to patients with, 212–213
clinical consequences of microorganisms within, 209–212
delay in wound healing, 209–211
infection, 211–212
skin graft and tissue flap infections, 212
contamination, colonization, and infection, 209

Midwest Nursing Centers Consortium Research Network, 750–751

Miglitol, 110

Military nursing, research on, relevance to research on disaster preparedness and response, 554–557
Triservice Nursing Research Program, 557, 560

Milstein's state of the science, in hospital response to acute-onset disasters, findings in, 569–572
foundation of, as defined by, 568–569
gaps in, 572–575

Mineral therapy, for osteoporosis, 123–125

Mirtazapine, 101

Moist wound healing, maintenance of, in topical wound management, 221–222

Monoamine oxidase inhibitors, 99

Monochromatic infrared energy, active wound therapy with, 229

Mourning, in evaluation of disaster's effect on culture, self, and identity, 437–438

Mylotarg. *See* Gemtuzumab ozogomicin.

Myocardial hypertrophy, in pathophysiology of heart failure, 136–137

N

Nateglinide, 110

National Assembly on School-Based Health Care, technical assistance from, 624–627

National curriculum. *See* Curriculum, nursing.

National Disaster Medical System, 483–485
definitive care, 484–485
field medical response, 484
patient transport, 484

National Fire Protection Association, regulations for healthcare organizations on emergency preparedness and response, 494

National Health Professions Preparedness Consortium, strategic plan from, 473–475

National Nursing Centers Consortium, 731–732
response to challenges, 733

National Response Plan, for disaster response and recovery, 485–486

Natriuretic peptides, in pathophysiology of heart failure, 137

Nefazodone, 101

Negative pressure wound therapy, active wound therapy with, 228–229

Nelfinavir, 160

Nevirapine, 159

Non-nucleoside reverse transcriptase inhibitors, 158

Northwestern United States, disaster nursing curriculum development based on vulnerability assessment in, **441–451**

Norvir. *See* Ritonavir.

Nucleoside reverse transcriptase inhibitors, 156–157

Nurse home visiting, with pregnant women, in Nurse-Family Partnership, **803–815**

Nurse practitioners, role in collaboration among key partners in school-based health centers, **689–697**
role in disaster planning and response, **511–521**
planning for response, 515–519
medical liability and malpractice, 516–517
mitigation phase, 518
practice acts, 515–516
preparation phase, 517–518
recovery phase, 519
response phase, 518–519
preparation for, 511–515
educational prerequisites, 512
educational standards for disaster care, 512–515
role in ethical issues in nurse-managed health care centers, **759–770**

Nurse-Family Partnership, nurse home visiting with pregnant women in, **803–815**

Nurse-managed health centers, 729–831
as a safety net to reduce health disparities, **729–738**
collaboration of public health and primary care nursing in development of, **771–778**
ethical considerations for, **759–770**
health care program for homeless children at, **791–801**
integrating primary and mental health care at, **779–790**
nurse home visiting with pregnant women, **803–815**
practice-based research networks at, **747–758**
sustaining nurse-managed practice, **739–745**
using Omaha system to document wellness needs of the elderly, **817–829**

Nurses, public health. *See* Public health nursing.
shortage of, role of staffing in prevention of medical errors, 15–17

Nursing education, disaster competency development and integration in, **453–467**
accreditation and regulatory agencies' role in, 455–456
continuing education providers' role in, 456
education and professional organizations' role in, 455
increasing effectiveness of responses to mass casualty incidents, 456–457
integrating mass casualty education into nursing curriculum, 458–463

International Nursing Coalition for Mass Casualty Education, 454–455
process to develop, 457–458
school of nursing and faculty roles in, 456
disaster nursing curriculum development based on vulnerability in Pacific Northwest, **441–451**
bioterrorism curriculum enhancement, 450
competencies and content, 450
deficits in, 447
defining and validating competencies, 445–446
endorsement of competencies by experts, 446–447
professional nursing mandate, 449
state and regional imperatives, 449
survey responses, 447–448
vulnerability assessment, 442–443
vulnerable populations, 443–445
national curriculum in emergency preparedness and response, **469–479**
American Association of Nurse Executives' survey on, 473
American College of Emergency Physicians task force on, 469–470
evaluation of outcomes, 476–478
initial public health workforce competency development, 471
International Nursing Coalition for Mass Casualty Education role in, 471–473
national curriculum development efforts, 475–476
National Health Professions Preparedness Consortium, 473–475
online development of, 475
nurse practitioners' role in disaster planning and response, preparation for, 511–515
educational prerequisites, 512
educational standards for disaster care, 512–515

Nursing practice, emergency preparedness and response in, concept development for, **419–430**
antecedants, 424
consequences, 424
defining attributes, 423–424
definition, 422–423
empirical referents, 424–425
literature review, 420–422
model case, 425–426
proposed definition of, 426
related concepts, 425
relevance for nursing, 426–427
homeland security challenges in, **481–497**
Centers for Disease Control's cooperative agreement on public health preparedness for, 489
compliance and regulatory issues for health care organizations, 489–493
Health Resources and Services Administration national bioterrorism hospital preparedness program, 489
incident command system/incident management system, 493–495
key knowledge base areas, 483–488
literature review of nursing's contributions, 482–483

Nursing schools. *See* Schools of nursing.

Nutrition, altered, and antiviral therapy in HIV and AIDS patients, 162–164
and wound healing in injection drug users, 354–355

Nutrition Revolution, resiliency programs in school-based health centers, 655–656

Nutritional knowledge, in overweight children, school-based program to increase, **661–669**

Nutritional support, in wound care at end of life, 292–293

O

Obesity, changing demographics and, 325–326
childhood, school-based approach to, **661–669**
example of model program for overweight adolescents, 664–666
prevalence, 662
rationale for program, 663
recommendations, 666–668
short- and long-term consequences of overweight in school-aged children, 662–663
successful programs, 663
meaning of, 326
skin and wound considerations in, **325–335**

Obesity (*continued*)
candidiasis, 327–328
incontinence dermatitis, 328
legal considerations, 330–332
planning for special equipment needs, 334
preparing for the future, 333–334
pressure ulcer precautions, 327
resedation phenomenon in, 333
surgical wounds, 328–330
panniculectomy, 329–330
use of clinical experts, 332–333

Oblimersen sodium, 91

Older adults, using Omaha System to document wellness needs of, **817–829**
wound care in, **267–279**
cognitive status and, 273–274
functional status and, 274–275
healing in, 269–270
sensory losses and, 270–273

Omaha System, use of to document wellness needs of the elderly, **817–829**

Oncology, antineoplastic therapy, innovations in, **77–94**

Organizational culture, for medication safety, creation of, **1–23**
See also Culture, hospital.

Orinase. *See* Tolbutamide.

Oritavancin, 70

Osteoporosis, **119–133**
economics of, 130–131
gender differences in, 121–122
incidence, 120–121
pathophysiology, 119–120
prevention and treatment, 122–130

Overlays. *See* Support surfaces.

Oxaliplatin, 77–78, 81

P

Pacific Northwest, disaster nursing curriculum development based on vulnerability assessment in, **441–451**

Pain, from infections and wounds in injection drug users, 356–357

Palliative care, of wounds, at end of life, 283–284

Panniculectomy, documentation for reimbursement, 329
skin and wound considerations in, 329–330

Patient education, as strategy for acquiring affordable medications for seniors, 60–61
on pressure ulcers, for people with spinal cord injury, 342–343
on wound care, for injection drug users, 348

Patients, role in preventing medication errors, 9

Pediatric Assessment Triage, use in mass casualty incidents, 527–528

Pediatric care, practical considerations for provision of in mass casualty incident, **523–533**
challenges in, defining pediatric patients, 524–525
error-prone drug calculations, 525
developing standards for, 524
modify emergency interventions as needed, 530–532
pediatric triage systems, 527–530
pre-event planning, 523–524, 525–527

Pediatrics, evaluation of children's metered-dose inhaler technique for asthma medications, **167–182**

Pharmaceutical therapy, for asthma. *See* Asthma.
for cancer. *See* Antineoplastic therapy.
for depression. *See* Antidepressive therapy.
for diabetes. *See* Diabetes.
for heart failure. *See* Heart failure.
for HIV and AIDS. *See* Antiviral therapy.
for osteoporosis. *See* Osteoporosis.
for seniors, strategies for acquiring affordable medications, **51–61**
resistance to. *See* Antibiotic resistance.

Physical health history, and wound healing in injection drug users, 353–354

Pill splitting, as strategy for acquiring affordable medications for seniors, 59–60

Pioglitazone., 111

Planning, for disasters. *See* Emergency preparedness and response.

Policies, adherence to, prevention of medication errors via, 10

Polifeprosan 20, with carmustine implant wafer, 78, 81–82

Post-traumatic stress disorder, in response to disasters, 538–540
assessment of three symptom clusters in, 544
comparison with acute stress disorder, 539

medications for treatment of, 547–548

Povidone iodine, wound debridement with, 242

Practice-based research networks, collaboration in, to reduce health care disparities, **747–758**

Practice. *See* Nursing practice.

Prandin. *See* Repaglinide.

Precose. *See* Acarbose.

Pregnant women, nurse home visiting with, **803–815**
from 1888 to 1930, 803–807
from 1978 to present, with Nurse-Family Partnership, 807–813

Prenatal care, nurse home visits with pregnant women, in Nurse-Family Partnership, **803–815**

Prescription drugs, antibiotic resistance, **63–75**
current trends in use of, **33–49**
health promotion drug use, 36
primary prevention drug use, 37–38
secondary prevention drug use, 38–39
tertiary prevention drug use, 40–43
See also Medications.

Pressure ulcers, **365–389**
causes, 366–367
chronic, microbiology of, **207–216**
clinical approach to patients with, 212–213
clinical consequences of microorganisms within, 209–212
delay in wound healing, 209–211
infection, 211–212
skin graft and tissue flap infections, 212
contamination, colonization, and infection, 209
classification system, 368
deep tissue injury, 369–370
epidemiology, 367
healing of, 374–375
scales of, 375
health care provider knowledge about, 376–380
in darkly pigmented skin, 368–369
in obese patients, prevention of, 327
in people with spinal cord injury, **337–347**
patient safety and, 375–376
prevention of, 372–374
quality improvement, 381–384
risk assessment, 370–372
support surfaces, role in prevention and treatment of, **251–265**

Prevention, of osteoporosis, 122–126

Prevention drugs, prescription, current trends in use of, 37–43
primary drugs, 37–38
secondary drugs, 38–39
tertiary drugs, 40–43

Primary care nursing, collaboration with public health nursing in
nurse-managed health center, **771–778**
mental health care integrated with, in nurse-managed center for clients with serious and persistent mental illness, **779–790**

Primary prevention drugs, prescription, current trends in use of, 37

Procedures, adherence to, prevention of medication errors via, 10

Program evaluation, for school-based health center programs and services, **711–724**

Proliferative responses, in process of tissue repair, 192–193

Propranolol, 138

Protease inhibitors, antiviral therapy with, in HIV infection, 158–160

Protein energy malnutrition, and antiviral therapy in HIV and AIDS patients, 162–164

Proteolytic changes, in chronic wounds, 199–200

Psychological care, in disasters, **535–550**
emotional care for victims, 541–547
behavioral therapy, 542, 545
cognitive strategies, 545
crisis intervention, 541
debriefing, 545–547
eye movement desensitization and reprocessing, 545
focused assessment, 541–542
emotional recovery and psychiatric sequelae, 537–540
acute stress disorder, 538
post-traumatic stress disorder, 538–540
human stress response, 535–536
key components of early intervention, 543
medication management, 547–548

Psychological care (*continued*)
responses to stress, 536–537
sources of stress, 536

Psychosocial health history, and wound healing in injection drug users, 354

Psychotherapy, for depression, 97

Public health nursing, collaboration with primary care nursing in nurse-managed health center, **771–778**
role in emergency preparedness and response, **499–509**
issues in preparing for
bioterrorism, nature of terrorism, 500–501
terminology, 500
role of public health nurses in
bioterrorism, 501–508
competencies, 502–503
develop improved preparedness, 504–505
local planning, 502
promote a balance, 507–508
respond to health consequences, 505–506
take action to prevent terrorism, 506–507

Public Health Service Act, funding opportunities for school-based health centers through, 618–619

Pulsed lavage, wound debridement with, 241

Pyoderma gangrenosum, in cancer patients, 297

Q

Quinupristin-dalfopristin, 70

R

Radiation therapy, for cancer patients, skin wounds due to, 310–317
care of, 314–317
experimental treatment strategies for, 317, 318–321
immediate and acute skin reactions, 311–312
late skin effects, 313

Raloxifene, 127

Ramoplanin, 70

Reconciliation, medication, in reduction of adverse drug events, 28–29

Regulatory agencies, role in disaster competency development and integration in nursing education, 455–456

Reimbursement, Medicare, for support surfaces, 258–262

Remembrance, in evaluation of disaster's effect on culture, self, and identity, 437–438

Remeron. *See* Mirtazapine.

Remodeling, of new tissues, in acute and chronic wounds, 193–195

Renin-angiotensin-aldosterone system, in pathophysiology of heart failure, 136

Repaglinide, 110

Repair, tissue, process of, in acute and chronic wounds, 192–195
hemostasis, inflammatory, and proliferative responses, 192–193
synthesis of new tissues and remodeling, 193–195

Rescriptor. *See* Delaviridine.

Research, community-based participatory, reduction of health care disparities via, **747–758**
on preparedness for mass casualty events, disaster, war, and terrorism, **551–565**
categorization of, and funding, 554
challenges in conducting, 552–553
importance of, 553–554
on health systems issues, 558–560
related to patient, family, and community, 557–558
related to providers, 554
relevance of military nursing research, 554–557
Triservice Nursing Research Program, 560
practice-based research networks, **747–758**

Research, nursing, school-based health centers sponsored by schools of nursing as sites for, 612–613

Resedation phenomenon, in obese patients, 333

Resiliency building, and risk reduction in adolescents, nurse practitioner's role in, in school-based health centers, **649–660**
comprehensive risk assessment, 650–655
confidentiality and the need to share information, 655
developmental stages and risk behaviors, 649–650
Healthy People **2010** critical health objectives, 650
programs for, 656–660
trust and authenticity, 656

Resilience, in evaluation of disaster's effect on culture, self, and identity, 435–436

Resistance, antibiotic, **63–75**
action plan for, 71–73
globalization and, 66–67
mechanisms of, 68–69
newer agents to combat, 69–71
scope of the problem, 65–66
types of, 67–68
drug-resistant *Streptococcus pneumoniae*, 68
methicillin-resistant *Staphylococcus aureus*, 67
vancomycin-intermediate and -resistant *Staphylococcus aureus*, 67–68

Revascularization, for arterial ulcers of lower extremity, 402

Revenues, from patient care, funding for school-based health centers from, 623–624

Reyataz. *See* Atazanavir.

Risendronate, 127

Risk reduction, in adolescents, nurse practitioner's role in resiliency building and, in school-based health centers, **649–660**
comprehensive risk assessment, 650–655
confidentiality and the need to share information, 655
developmental stages and risk behaviors, 649–650
Healthy People 2010 critical health objectives, 650
programs for, 656–660
trust and authenticity, 656

Ritonavir, 160

Rosiglitazone, 111, 114, 116

Rosuvastatin, 112–113

S

Safety net, nurse-managed health centers as, to reduce health disparities, **729–738**

Safety, medication, creating an organizational culture for, **1–23**

Safety, patient, pressure ulcers and, 375–376

Sam-e, 102

Saquinavir, 161

School-based health centers, 595–722
childhood obesity, school-based approach to, **661–669**
collaborating with key school partners, **689–697**
cultural aspects of working with students enrolled in, **637–647**
evaluation of program effectiveness, **711–724**
funding, technical assistance, and other resources for, **619–636**
history and overview of, **595–606**
funding for, 603
future of, 603–604
health promotion, 602
models of sponsorship for, 602–603
origins of, 596–600
types of health services in, 601–602
impact of violence on adolescents, **671–679**
interdisciplinary teamwork in, **699–710**
nurse practitioner's role in adolescent risk reduction and resiliency building in, **649–660**
school of nursing sponsorship, challenges and barriers of, **607–617**
STI-HIV prevention model for, **681–688**
Schools of nursing. *See also* Nursing education.
role in disaster competency development and integration in nursing education, 456
sponsorship of school-based health centers by, **607–617**
benefits of, 608–613
faculty practice site, 611
impetus for, 608
interdisciplinary learning, 611–612
laboratory for nursing student learning, 609–611
sites for nursing research, 612–613
challenges for, 613–616
commitment from university administration, 613–614
cultivating trust and mutual support, 614–615
developing management skills, 614
different perspectives on, 615–616

Secondary prevention drugs, prescription, current trends in use of, 38–39

Selective serotonin reuptake inhibitors, 100–101

Self, impact of disaster on culture, identity, and, **431–440**

Senior citizens, strategies for acquiring affordable medications for, **51–61**
generic medications, 53–57
legislative action, 52–53
patient education and advocacy, 60–61
resources for, 57–59
splitting pills, 59–60

Sensory losses, in older adults, impact on wound care, 270–273

Serious and persistent mental illness. *See* Mental illness.

Serzone. *See* Nefazodone.

Sexually transmitted infections, prevention of, model program in school-based health center, **681–688**

Shortage, nursing, role of staffing in prevention of medical errors, 15–17

Six-sigma quality, in pressure ulcer care, 378–380

Skilled nursing facilities, coverage and reimbursement for support surfaces in, 263

Skin equivalents, active wound therapy with, 229–230

Skin grafts, failure of, due to infection, 212

Skin integrity, challenges of obesity and, **325–335**

Spinal cord injury, pressure ulcers in people with, **337–347**
compliance with care, 343–344
education of health professionals, 345
evidence-based practice recommendations, 338–339
patient education, 342–343
prevention and management, 341–342
risk of pressure ulcers, 339–341
statistics on, 337–338
telerehabilitation, 344

St. John's wort, 102

Staffing, role in prevention of medical errors, 15–17

Stafford Disaster Relief and Emergency Assistance Act, 486

Standardization, of orders, in reduction of adverse drug events, 29

Staphylococcus aureus, methicillin-resistant, 67
vancomycin-intermediate, 67–68
vancomycin-resistant, 67–68

Starlix. *See* Nateglinide.

START algorithm, for pediatric triage in mass casualty incidents, 527–528

State of the science, in hospital response to acute-onset disasters, **567–579**
Milstein's state of science, findings in, 569–572
foundation of, as defined by, 568–569
gaps in, 572–575
value of examining, 567–568
value of review in patient care, 575–576

Statin therapy, in diabetics, 111–113

Stavudine, 156, 157

Strategic National Stockpile, of Centers for Disease Control, 486

Streptococcus pneumoniae, drug-resistant, 68

Stress, crisis incident stress debriefing for disaster victims, 545–547
human response to, in disasters, 535–537

Students, nursing, learning opportunities at school-based health centers sponsored by schools of nursing, 609–611

Students, school, exposure to health career opportunities in school-base health centers, 641–644

Substance abuse, injection drug users, wound care issues in, **349–363**

Superfund Amendments and Reauthorization Act, 494

Support surfaces, for prevention and treatment cf pressure ulcers, **251–265**
background on, 251–252
characteristics of, 256
coverage and reimbursement, 258
professional practice fact sheet on, 259–262
data on efficacy of, 253–254
for prevention, 253
for treatment, 253–254
requirements for, 254–256
selection of, 256–258

Surgical debridement, of wounds, 240

Surgical wounds, considerations in obese patients, 328–330
delayed healing, 328–329
panniculectomy, 329–330
documentation for reimbursement, 329

Sustiva. *See* Efavirenz.

Synthesis, of new tissues, in acute and chronic wounds, 193–195

T

Taxotere. *See* Docetaxel.

Teaching, patient. *See* Patient education.

Teamwork, interdisciplinary, in a school-based health center, **699–710**
role in prevention of medical errors, 15

Technical assistance, for school-based health centers, **619–636**
Medicaid, 629–630
National Assembly on School-Based Health Care, 626–629
state resources, 630–631

Technology, interventions for preventing medication errors, 10–12

Teen Talk, resiliency programs in school-based health centers, 657

Telerehabilitation, for people with spinal cord injury, 343–344

Telithromycin, 70

Tenofovir, 158

Terminally ill patients, care of chronic wounds in, 282

Terrorism. *See also* Bioterrorism.
public health agencies' role in prevention of, 506–507

Tertiary prevention drugs, prescription, current trends in use of, 40–43

Thiazolodinediones, 111

Tissue flaps, failure of, due to infection, 212

Tissue injury. *See* Wounds and Wound care.

Tissue repair. *See* Repair, tissue.

Tolbutamide, 110

Topical wound management, guidelines for, **217–231**
active therapies, 227–230
electrical stimulation, 229
growth factors, 228
matrix metalloproteinase inhibitors, 228
negative pressure wound therapy, 228–229
dressing selection, 224–227
deep dry wounds, 224–225
deep wet wounds, 224
human skin equivalents, 229–230
monochromatic infrared energy, 229
shallow dry wounds, 226–227
shallow wet wounds, 225–226
principles of, 217–223
control of bacterial loads, 218–221
debridement, 218
establishment of open wound edges, 221
exudate management, 221–222
maintenance of moist wound surface, 222–223
maintenance of protected insulated wound surface, 223

Tositumomab, 78, 84
with iodine 131, 78, 84

Transcultural health care, perspectives on disaster in, 432–433

Trauma, due to disaster, feelings associated with, 435–436

Trazodone, 101

Triage systems, pediatric, use in mass casualty incidents, 527–530

Trisemox. *See* Arsenic trioxide.

Triservice Nursing Research Program, 557, 560

U

Ulcers, arterial and venous of lower extremity, **391–410**

Ulcers, pressure
causes of, 366–367
chronic leg and, microbiology of, **207–216**
clinical approach to patients with, 212–213
clinical consequences of microorganisms within, 209–212
delay in wound healing, 209–211
infection, 211–212
skin graft and tissue flap infections, 212
contamination, colonization, and infection, 209
classification system, 368
deep tissue injury, 369–370
epidemiology, 367
healing of, 374–375
scales of, 375
health care provider knowledge about, 376–380
in darkly pigmented skin, 368–369
in obese patients, prevention of, 327
in people with spinal cord injury, **337–347**
compliance with care, 343–344

Ulcers (*continued*)
education of health professionals, 345
evidence-based practice recommendations, 338–339
patient education, 342–343
prevention and management, 341–342
risk of pressure ulcers, 339–341
statistics on, 337–338
telerehabilitation, 344
patient safety and, 375–376
prevention of, 372–374
quality improvement, 381–384
risk assessment, 370–372
support surfaces and, **251–265**
support surfaces, role in prevention and treatment of, **251–265**

V

Vancomycin-intermediate *Staphylococcus aureus*, 67–68

Vancomycin-resistant *Staphylococcus aureus*, 67–68

Vasculitis, atypical wounds in cancer patients due to, 297

Velcade. *See* Bortezomib.

Venlafaxine, 101

Venous insufficiency, chronic, in injection drug users, 352

Venous ulcers, of lower extremity, **391–410**
anatomy, 392–393
classification, 400–401
pathophysiology, 398–400
risk factors, 401
treatment, 403–405

Vesicants, antidotes to, in treatment of chemotherapy extravasation wounds, 308–309

Videx. *See* Didanosine.

Violence, youth, impact on adolescents, and role of school-based health centers, **671–679**

Viracept. *See* Nelfinavir.

Viral load, in HIV infection, 154

Viral progression, in HIV infection, 151–152

Viramune. *See* Nevirapine.

Viread. *See* Tenofovir.

Virulizin, 91

Vision losses, in older adults, impact on wound care, 272–273

Vitamin D, for osteoporosis prevention, 124–125

Vitamin K, for osteoporosis prevention, 125

Vitamin therapy, for osteoporosis, 123–125

Vulnerability, in evaluation of disaster's effect on culture, self, and identity, 435–436

Vulnerability assessment, disaster nursing curriculum development based on, in Pacific Northwest, **441–451**
bioterrorism curriculum enhancement, 450
competencies and content, 450
deficits in, 447
defining and validating competencies, 445–446
endorsement of competencies by experts, 446–447
professional nursing mandate, 449
state and regional imperatives, 449
survey responses, 447–448
vulnerability assessment, 442–443
vulnerable populations, 443–445

Vulnerable populations, in developing disaster nursing curriculum, 443–445

W

Walking Club, resiliency programs in school-based health centers, 657–658

War. *See* Mass casualty incidents *and* Emergency preparedness and response.

Weapons of Mass Destruction Act of 1996, 487

Web resources, on disaster preparedness, 542

Wellbutrin. *See* Bupropion.

Wellness needs, of the elderly, use of Omaha system to document, **817–829**

Whirlpool therapy, wound debridement with, 241

Wound care, at end of life, **281–294**
nursing process with, 288–293
debridement, **233–249**
benefits of, 233–235
evidence-based practice and, 237–238
healing process, barriers and facilitators of, 235
in topical management, 218
methods of, 238–246
factors influencing choice of, 239
special role of, 236–237
in cancer patients, **295–323**
atypical wounds associated with cancer, 297
cancer development in chronic wounds, 297–304
biopsy of, 298

causes of, 298
malignant cutaneous wounds, 298–304
chemotherapy extravasation wounds, 303–310
impaired wound healing in, 296
radiation therapy, skin wounds due to, 310–317
in injection drug users, **349–363**
abscess and infection in, 351–352
chronic venous insufficiency in, 352–353
drug use history, 355–356
nutrition and, 354–355
pain and, 356–357
patient teaching for, 358–360
physical health history and, 353–354
prevention of wounds in, 360–361
psychosocial health history and, 354
wound assessment in, 357–358
in obese patients, **325–335**
candidiasis, 327–328
incontinence dermatitis, 328
legal considerations, 330–332
preparing for the future, 333–334
pressure ulcer precautions, 327
surgical wounds, 328–330
panniculectomy, 329–330
use of clinical experts, 332–333
in older adults, **267–279**
cognitive status and, 273–274
functional status and, 274–275
healing in, 269–270
sensory losses and, 270–273
lower extremity arterial and venous ulcers, **391–410**
anatomy, 392–393
history and physical examination, 393–398
treatment, 402–407
pressure ulcers, **365–389**
causes, 366–367
classification system, 368
deep tissue injury, 369–370
epidemiology, 367
healing of, 374–375
scales of, 375
health care provider knowledge about, 376–380
in darkly pigmented skin, 368–369
in people with spinal cord injury, **337–347**
compliance with care, 343–344
education of health professionals, 345
evidence-based practice recommendations, 338–339
patient education, 342–343
prevention and management, 341–342
risk of pressure ulcers, 339–341
statistics on, 337–338
telerehabilitation, 344
patient safety and, 375–376
prevention of, 372–374
quality improvement, 381–384
risk assessment, 370–372
support surfaces, role in prevention and treatment of, **251–265**
support surfaces, **251–265**
background on pressure ulcers and, 251–252
characteristics of, 256
coverage and reimbursement, 258
professional practice fact sheet on, 259–262
data on efficacy of, 253–254
for prevention, 253
for treatment, 253–254
requirements for, 254–256
selection of, 256–258
topical wound management, guidelines for, **217–231**
active therapies, 227–230
dressing selection, 224–227
principles of, 217–223

Wound healing, delay in, due to microorganisms, 209–211

Wound, Ostomy and Continence Nurses Society, professional fact sheet on Medicare coverage for support surfaces, 259–262

Wounds, acute and chronic, overview of, **191–205**
changes in healing trajectory and microenvironment in chronic, 195–200
bacteria in, 196–197
growth factor and inflammatory changes in, 197–199
proteolytic changes in, 199–200
implications for management of, 200–201
process of tissue repair, 192–195
hemostasis, inflammatory, and proliferative responses, 192–193

Wounds (*continued*)
synthesis of new tissues and remodeling, 193–195
chronic leg and pressure ulcers,
microbiology of, **207–216**
clinical approach to patients with, 212–213
clinical consequences of microorganisms within, 209–212
delay in wound healing, 209–211
infection, 211–212
skin graft and tissue flap infections, 212
contamination, colonization, and infection, 209
malignant cutaneous, 298–304

X

Xeloda. *See* Capecitabine.

Y

Youth violence, impact on adolescents, and role of school-based health centers, **669–677**

Z

Zalcitabine, 156, 157
Zerit. *See* Stavudine.
Zetia. *See* Ezetimibe.
Zevalin. *See* Ibritumomab.
Ziagen. *See* Abacavir.